View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)

This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...

Carole Braudeau
  • Carole Braudeau

Credit Morning 05/02/2024

BBVA proposes merging with Banco Sabadell to create a European leaderUnited Group: e& has considered a potential acquisition of United Group (Bloomberg)>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 02/05/2024

BBVA propose à Sabadell une fusion afin de créer un leader européenUnited Group : e& envisagerait une possible acquisition de United Group (Bloomberg)>...

Jan Frederik Slijkerman ... (+5)
  • Jan Frederik Slijkerman
  • Jeroen van den Broek
  • Jesse Norcross
  • Nadège Tillier
  • Timothy Rahill

Coffee, Croissants & Credit/Aroundtown, Public Storage and WP Carey

Real Estate - Aroundtown shows successful result of GBP & USD Hybrid exchange and tender. Public Storage 1Q24: Slightly softer but no real concerns for credit investors. WP Carey 1Q24: Slight miss, but strong cash balance and liquidity

 PRESS RELEASE

Press Release: Beyfortus real-world evidence published in The Lancet s...

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the o...

 PRESS RELEASE

Communiqué de presse : Des données de vie réelle concernant Beyfortus ...

Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS De nouvelles données de vie réelle montrent que Beyfortus (nirsevimab) a permis de réduire sensiblement les infections des voies respiratoires inférieures dues au VRS chez les nourrissons, de même que les hospitalisations, au cours de la saison virale 2023-2024, compa...

Safran S.A.: 1 director

A director at Safran S.A. sold 2,095 shares at 208.000EUR and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

Aroundtown SA successfully completes GBP and USD exchange and tender o...

Aroundtown SA (IRSH) Aroundtown SA successfully completes GBP and USD exchange and tender offers, and including previous Euro transactions accepts a total combined volume of €2.8 billion 01-May-2024 / 10:08 CET/CEST The issuer is solely responsible for the content of this announcement. THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF APPLICABLE LAWS OR REGULATIONS  AROUNDTOWN SUCCESSFULLY COMPLET...

 PRESS RELEASE

EQS-News: Aroundtown SA successfully completes GBP and USD exchange an...

EQS-News: Aroundtown SA / Key word(s): Tender Offer/Financing Aroundtown SA successfully completes GBP and USD exchange and tender offers, and including previous Euro transactions accepts a total combined volume of €2.8 billion 01.05.2024 / 10:07 CET/CEST The issuer is solely responsible for the content of this announcement. THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF APPLICABLE LAWS...

Sanofi: 1 director

A director at Sanofi bought 1,000 shares at 91.380EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...

 PRESS RELEASE

Press Release: Annual General Meeting of April 30, 2024

Press Release: Annual General Meeting of April 30, 2024 Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024Board composition: renewal of two Directors and appointment of three new Independent Directors Paris, April 30, 2024. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2024, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the indi...

 PRESS RELEASE

Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024

Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024 Assemblée Générale Annuelle du 30 avril 2024 Approbation des comptes sociaux et des comptes consolidés de l’exercice 2023Distribution d’un dividende en numéraire de 3,76 euros par action, dont la mise en paiement interviendra le 15 mai 2024Composition du Conseil d’administration : renouvellement de deux administrateurs et nomination de trois nouveaux administrateurs indépendants Paris, le 30 avril 2024. L’Assemblée Générale Mixte des actionnaires de Sanofi s’est réunie le 30 avril 2024, sous la présidence de Frédéric ...

Olfa Taamallah ... (+2)
  • Olfa Taamallah
  • Yan Derocles

Safran : Neutral vs Outperform… pending the CMD

>Neutral vs Outperform - TP revised to € 220 - After gains of 30.8% ytd, the stock is now trading on best in class multiples for the European aerospace sector, with an EV/EBIT of 18.2x (premium of c.25%) and a discount limited to c5% vs GE Aero. Admittedly, Safran is the best-quality stock in our coverage universe and we do not see any clouds on the horizon, but investors seem to have already priced in an upward revision of the 2024 guidance. Furthermore, we believe t...

Olfa Taamallah ... (+2)
  • Olfa Taamallah
  • Yan Derocles

Safran : Neutre vs Surperformance… en attendant le CMD

>Neutre vs Surperformance - OC révisé à 220 € - Après une appréciation de 30.8% YtD, le titre se traite désormais sur des multiples de best in class dans le secteur aéronautique européen avec un multiple VE/EBIT de 18.2x (prime de c25%) et une décote limitée à c5% par rapport à GE Aero. Certes, Safran est le titre le plus qualitatif dans notre univers de couverture et nous ne percevons pas de nuage à l’horizon mais les investisseurs nous semblent avoir déjà intégré un...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch